2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Michael Wagner, MD, discusses the safety profile of nivolumab plus ipilimumab in patients with angiosarcoma.
Michael Wagner, MD, an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Research Center, discusses the safety profile of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with angiosarcoma.
In the phase 2 DART trial (NCT02834013), no surprising safety signals were observed. The toxicity profile was in line with what had been expected from a nivolumab and ipilimumab combination, Wagner says. Most of the toxicities reported were autoimmune related; however, due to the small sample size of patients, it was difficult to generalize safety takeaways from the study, Wagner explains.
Overall, the study results did not indicate that patients with angiosarcoma are at higher risk for any particular toxicity, Wagner adds. A larger cohort would be needed to confirm this, Wagner concludes.